Full-Time

Clinical Research Engineer

Noctrix Health

Noctrix Health

51-200 employees

Prescription wearable neuromodulation for RLS.

Compensation Overview

$130k - $150k/yr

+ Annual bonus eligibility

Pleasanton, CA, USA

Hybrid

At least three days per week onsite.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Python
Git
SQL
Machine Learning
Quality Assurance (QA)
C/C++
HIPAA
Data Analysis

Get referred to Noctrix Health

See people who can refer or advise you

Requirements
  • A Bachelor's degree in Engineering, Biomedical Engineering, Electrical Engineering, Computer Science, or a related technical discipline with 5+ years of relevant industry experience, or a Master's degree with 3+ years of relevant experience.
  • Experience developing, testing, or supporting medical devices, wearable health technologies, or similar regulated products.
  • Experience working across software development, data analysis, testing, and embedded systems.
  • Experience supporting research or product development from concept through commercialization within a Design Control environment.
  • Hands-on experience developing and executing verification and validation testing within a regulated product development environment.
  • Experience analyzing physiological signals, biosensor data, device data, or similar time-series datasets.
  • Strong proficiency in Python for data analysis, algorithm development, automation, or software development.
  • Experience with statistical analysis and interpretation of experimental and clinical datasets.
  • Understanding of signal processing and digital signal analysis methodologies.
  • Familiarity with algorithm and machine learning model development and testing methods.
  • Strong technical writing skills with experience producing protocols, reports, specifications, and other controlled documentation.
  • Strong analytical and troubleshooting skills to investigate and resolve complex technical problems.
  • Ability to independently manage multiple projects and priorities in a fast-paced, cross-functional environment.
  • Ability to clearly communicate technical findings to technical and non-technical stakeholders.
Responsibilities
  • Develop Python-based tools, algorithms, analysis pipelines, and automation frameworks to improve research efficiency, engineering productivity, and data quality.
  • Analyze clinical, physiological, and device datasets to identify trends, generate insights, and support product and clinical decision-making.
  • Perform physiological signal processing, waveform analysis, and interpretation of biosensor and device-generated data.
  • Develop and execute verification and validation protocols for software, firmware, algorithms, and medical device systems.
  • Contribute to the design, development, and testing of firmware components and embedded systems used within medical devices.
  • Support device characterization, use-case testing, performance evaluations, and root cause investigations.
  • Develop automated testing and data analysis workflows to improve the efficiency and repeatability of research and engineering activities.
  • Apply statistical methods to experimental and clinical datasets and interpret results for clinical research and product development.
  • Support algorithm and machine learning model development, evaluation, and testing where applicable.
  • Collaborate with cross-functional teams to define technical requirements, design experiments, develop and test systems, and solve complex technical problems.
  • Support clinical research studies through data collection, analysis, technical troubleshooting, and interpretation of study results.
  • Prepare technical documentation, including research findings, technical specifications, test protocols, test reports, and engineering records.
  • Document technical and research activities in accordance with applicable Quality System and regulatory requirements.
  • Partner with Clinical Affairs, Regulatory Affairs, Quality Assurance, Product Management, and Engineering to advance safe, effective, and patient-centered solutions.
Desired Qualifications
  • Experience supporting clinical research studies, clinical data analysis, or human subjects research.
  • Experience with C++, SQL, Git, and modern software development workflows.
  • Experience developing automated test systems, data processing pipelines, or research tools.
  • Experience developing or evaluating algorithms and machine learning models using physiological or clinical data.
  • Experience with embedded firmware development and testing.
  • Strong understanding of software development principles and version control practices.
  • Familiarity with FDA Design Controls and medical device Quality Management Systems.
  • Knowledge of Good Clinical Practice, HIPAA, patient data privacy requirements, and healthcare data security best practices.
  • Experience working with wearable medical devices, neurostimulation technologies, biosensors, or other connected health products.

Noctrix Health makes prescription wearable therapy for Restless Legs Syndrome using the NTX100 Tonic Motor Activation System (Nidra). It uses leg bands to stimulate the peroneal nerves at night, producing gentle muscle activation that reduces RLS sensations and improves sleep. The device is prescribed through healthcare providers for adults with moderate-to-severe, medication-refractory RLS and is backed by FDA De Novo clearance in 2023 following a Breakthrough Device Designation and a multi-center trial. The goal is to establish wearable therapeutics as a standard non-drug treatment option to improve sleep for people with RLS.

Company Size

51-200

Company Stage

Acquired

Total Funding

$90.5M

Headquarters

Pleasanton, California

Founded

2018

Get referred to Noctrix Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Noctrix reported about $24 million annual run-rate revenue before closing, already commercializing.
  • CMS issued dedicated HCPCS codes and payment in 2024, reducing patient access friction.
  • ResMed can cross-sell Nidra through existing sleep clinics, HME partners, and international distribution.

What critics are saying

  • ResMed must integrate Noctrix by late 2026 while preserving sales momentum and reimbursement.
  • RLS prescriptions depend on sleep physicians and HMEs; coverage changes would choke adoption quickly.
  • If Nidra stalls below ResMed's expectations, the asset becomes a small, deprioritized portfolio experiment.

What makes Noctrix Health unique

  • Nidra is FDA De Novo-cleared, drug-free TOMAC for medication-refractory RLS.
  • AASM guidelines recognized peroneal nerve stimulation in 2024, validating Noctrix's mechanism.
  • ResMed completed the $340 million acquisition on June 1, 2026, giving channel reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

2%

2 year growth

0%
Sleep Review Magazine
May 5th, 2026
Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker.

Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker. Resmed will acquire the manufacturer of an fda-cleared nerve stimulation device for refractory RLS, a move that leverages its existing sleep physician and home medical equipment channels. Key takeaways: * Resmed has signed an agreement to acquire Noctrix Health, maker of the Nidra device, for a purchase price of $340 million. * The acquisition targets the estimated 7% of adults globally affected by RLS, a population with meaningful overlap with obstructive sleep apnea. * The transaction is expected to close around June 1, 2026, with revenue to be reported within Resmed's Americas Devices category. Resmed has signed a $340 million agreement to acquire Noctrix Health, a medical device company with an FDA de novo classified product indicated for the treatment of refractory moderate-to-severe restless legs syndrome (RLS). The flagship product, Nidra, is a noninvasive nerve stimulation device. The acquisition marks Resmed's expansion into adjacent sleep health markets, targeting what is considered the third-most-prevalent sleep disorder after obstructive sleep apnea (OSA) and insomnia. RLS affects approximately 7% of adults globally, including around 17 million people in the US, and has a meaningful overlap with OSA. "RLS treatments from Noctrix are noninvasive, clinically proven, and drug-free, just like our CPAP/APAP and bilevel therapies," said Michael Farrell, CEO and chairman of the board at Resmed, during the company's third-quarter earnings call. Resmed, which has been an investor in Noctrix since 2024, plans to leverage its established market access to scale the therapy. Prescriptions for the device are written predominantly by sleep physicians and flow through the same home medical equipment (HME) and durable medical equipment (DME) delivery channels where Resmed currently holds a leading market share. "The reach of our Resmed brand among sleep physicians and HME providers as well as our national and international distribution channel strength makes us the best owner of this scarce asset," Farrell said. The transaction is targeted to close on or around June 1, 2026. Noctrix currently has an annual run rate revenue of approximately $24 million, which Resmed notes is growing at a faster rate and operating at a higher gross margin than Resmed's core business. Once closed, Noctrix's financials will be reported within Resmed's Americas Devices category. The acquisition is expected to result in an approximate $0.02 reduction in non-GAAP earnings per share for the fourth quarter of fiscal year 2026 as Resmed continues to invest in research and development and sales and marketing for the new asset.

Simply Wall St
May 1st, 2026
ResMed names new CFO and acquires Noctrix Health to expand into neurology

ResMed has appointed Aaron Bloomer as chief financial officer, replacing retiring CFO Brett Sandercock, and agreed to acquire Noctrix Health, a medical device company specialising in restless leg syndrome treatments. The moves mark a strategic shift for ResMed, which is primarily known for sleep apnoea devices and related software. The Noctrix acquisition expands the company's portfolio into neurological conditions affecting sleep quality, broadening its clinical scope beyond traditional respiratory care. Investors will be watching how ResMed balances capital allocation between its core sleep apnoea business and new neurology-related devices. Integration risks around Noctrix, including regulatory and reimbursement hurdles, remain key factors to monitor. At $213.81, ResMed shares trade approximately 26% below the analyst target of $288.21.

Michael West Media
May 1st, 2026
Snoring leader buys restless leg syndrome device maker - Michael West

Sleep apnoea company Resmed has acquired a California firm that makes a device for patients with restless leg syndrome, the third-biggest sleep disorder.

FinSMEs
Sep 2nd, 2025
Noctrix Health Raises Up To $33.5M in Debt and Equity Funding

Noctrix Health raises up to $33.5M in debt and equity funding.

FinancialContent
Aug 29th, 2025
Noctrix Health Raises $33.5M for RLS Therapy

Noctrix Health has raised $33.5 million to accelerate the U.S. commercialization of its Nidra® TOMAC therapy for Restless Legs Syndrome (RLS). The funding includes contributions from Blue Venture Fund, Sandbox Clinical Ventures, and a debt facility from Bridge Bank. The company has also expanded its leadership team, appointing Ivan Lubogo as Chief Commercial Officer and promoting Jonathan Charlesworth, Ph.D., to Chief Scientific Officer. Mark Verratti joins the Board of Directors.